These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 27749649)
1. Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia. Melvin AJ; Montepiedra G; Aaron L; Meyer WA; Spiegel HM; Borkowsky W; Abzug MJ; Best BM; Crain MJ; Borum PR; Graham B; Anthony P; Shin K; Siberry GK; Pediatr Infect Dis J; 2017 Jan; 36(1):53-60. PubMed ID: 27749649 [TBL] [Abstract][Full Text] [Related]
2. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J; Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589 [TBL] [Abstract][Full Text] [Related]
3. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151 [TBL] [Abstract][Full Text] [Related]
4. A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia. Langslet G; Breazna A; Drogari E J Clin Lipidol; 2016; 10(5):1153-1162.e3. PubMed ID: 27678432 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Zieve F; Wenger NK; Ben-Yehuda O; Constance C; Bird S; Lee R; Hanson ME; Jones-Burton C; Tershakovec AM Am J Cardiol; 2010 Mar; 105(5):656-63. PubMed ID: 20185012 [TBL] [Abstract][Full Text] [Related]
6. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516 [TBL] [Abstract][Full Text] [Related]
7. Effects of statins (atorvastatin) on serum lipoprotein levels in patients with primary hyperlipidemia and coronary heart disease. Jurukovska-Nospal M; Arsova V; Levchanska J; Sidovska-Ivanovska B Prilozi; 2007 Dec; 28(2):137-48. PubMed ID: 18356785 [TBL] [Abstract][Full Text] [Related]
8. Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275). Nixon DE; Bosch RJ; Chan ES; Funderburg NT; Hodder S; Lake JE; Lederman MM; Klingman KL; Aberg JA; J Clin Lipidol; 2017; 11(1):61-69. PubMed ID: 28391912 [TBL] [Abstract][Full Text] [Related]
10. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study. Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. McCrindle BW; Ose L; Marais AD J Pediatr; 2003 Jul; 143(1):74-80. PubMed ID: 12915827 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA; JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291 [TBL] [Abstract][Full Text] [Related]
13. Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial. Wangpatharawanit P; Sungkanuparph S Clin Infect Dis; 2016 Sep; 63(6):818-20. PubMed ID: 27402817 [TBL] [Abstract][Full Text] [Related]
14. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. Blom DJ; Hala T; Bolognese M; Lillestol MJ; Toth PD; Burgess L; Ceska R; Roth E; Koren MJ; Ballantyne CM; Monsalvo ML; Tsirtsonis K; Kim JB; Scott R; Wasserman SM; Stein EA; N Engl J Med; 2014 May; 370(19):1809-19. PubMed ID: 24678979 [TBL] [Abstract][Full Text] [Related]
15. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465 [TBL] [Abstract][Full Text] [Related]
16. Impact of HIV infection and HAART on serum lipids in men. Riddler SA; Smit E; Cole SR; Li R; Chmiel JS; Dobs A; Palella F; Visscher B; Evans R; Kingsley LA JAMA; 2003 Jun; 289(22):2978-82. PubMed ID: 12799406 [TBL] [Abstract][Full Text] [Related]
17. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E; Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231 [TBL] [Abstract][Full Text] [Related]
18. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Strandberg TE; Feely J; Sigurdsson EL; Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694 [TBL] [Abstract][Full Text] [Related]